<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04273516</url>
  </required_header>
  <id_info>
    <org_study_id>3498</org_study_id>
    <nct_id>NCT04273516</nct_id>
  </id_info>
  <brief_title>Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)</brief_title>
  <acronym>AREST-ESUS</acronym>
  <official_title>Rivaroxaban Plus ASA Efficacy and Safety in Embolic Stroke of Undetermined Source :A Randomized, Double Blind, Placebo Controlled, Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mazandaran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mazandaran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 17% of all patients with stroke are classified as having ESUS, which is
      associated with a considerable rate of stroke recurrence 4-5 % per year.

      Despite recent scientific advances in acute ischemic stroke treatment in recent
      decades,consensus treatment of all guidelines is still ASA
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, parallel, placebo-controlled pilot study on ischemic
      stroke of undetermined source which will be conducted in Bu Ali Sina hospital in Sari, Iran.

      Patients with recent stroke with criteria of ESUS, will be randomized to Rivaroxaban 2.5 mg
      BID plus ASA 80 mg daily or ASA 80 mg plus placebo (1:1 ratio) and have visit every 3 month
      until 1 year
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of stroke recurrence</measure>
    <time_frame>Rate of stroke recurrence during one year fallow up</time_frame>
    <description>Number of stroke events during 1 year of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of major bleeding</measure>
    <time_frame>During 1 year of study</time_frame>
    <description>Rate of major bleeding according to criteria of the International Society of Thrombosis and Hemostasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of stroke or systemic embolisms</measure>
    <time_frame>During 1 year of study</time_frame>
    <description>Number of stroke or systemic embolisms recurrence during 1 year of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>During 1year of study</time_frame>
    <description>Number of all cause mortality during study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-major bleeding</measure>
    <time_frame>During 1year of study</time_frame>
    <description>Rate of non-major bleeding according to criteria of the International Society of Thrombosis and Hemostasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of intracranial bleeding</measure>
    <time_frame>During 1year of study</time_frame>
    <description>Rate of ICH during study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of fatal bleeding</measure>
    <time_frame>During 1 year of study</time_frame>
    <description>Rate of fatal bleeding in any site</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Stroke</condition>
  <condition>Prevention</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet Rivaroxaban 2.5 mg 2 times daily plus ASA 80 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tab ASA 80 mg daily plus placebo ( similar to rivaroxaban tablet) 2 times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 2.5 Mg Oral Tablet</intervention_name>
    <description>Tablet Rivaroxaban 2.5 mg 2 times daily add to standard treatment ASA 80 mg daily</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Axabin 2.5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban placebo tablets</intervention_name>
    <description>Placebo tablets add to ASA 80 mg daily that is standard treatment</description>
    <arm_group_label>Comparator</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. signing the inform consent

          2. recent ischemic stroke ( 7-60) days with criteria of ESUS

          3. only one risk factors of potential embolic source including:

               1. PTFV1 in standard ECG ≥0.05 mm.s or ≥0.005 mv.s

               2. LVH in standard ECG( Sokolow index≥ 35 mm)

               3. Moderate or severe valvular disorder on echocardiography (except MS)

               4. Evidence of LVH on echocardiography

               5. PFO without indication of occlusion

               6. Left atrium enlargement in echocardiogeraphy

        Exclusion Criteria:

          1. History of hypersensitivity to the investigational medicinal product

          2. Indication for anticoagulation

          3. Indication for dual antiplatelet therapy

          4. Contraindication to investigational medications

          5. History of intracranial, intraocular, spinal, retroperitoneal or atraumatic
             intra-articular bleeding

          6. Gastrointestinal bleed or major surgery within 3 months

          7. Planned or likely revascularization (any angioplasty or vascular surgery) within the
             next 3 months

          8. HAS-BLED score &gt;3

          9. Severe non-cardiovascular comorbidity with life expectancy &lt; 3 months

         10. Severe renal failure, defined as Glomerular Filtration Rate (GFR) &lt;15ml/min, Dialysis,
             transplant, Cr &gt;2.26 mg/dL

         11. Severe hepatic insufficiency, Cirrhosis or Bilirubin &gt;2x Normal or AST/ALT/AP &gt;3x
             Normal

         12. Modified Rankin Scale of &gt;=4 at time of randomization or inability to swallow
             medications.

         13. Hemorrhagic transformation of infarction detected by Brain CT or MRI at the time of
             drug application
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Athena Sharifi Razavi</last_name>
    <phone>00989113510136</phone>
    <email>athena.sharifi@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Athena Sharifi Razavi</name>
      <address>
        <city>Sari</city>
        <state>Mazandaran</state>
        <zip>4818777111</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bu Ali Sina Hospital</name>
      <address>
        <city>Sari</city>
        <state>Mazandaran</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Monireh Gazaeian</last_name>
      <email>ghazaeianm@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Neurology Centre</last_name>
      <phone>00981133343014</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 15, 2020</study_first_submitted>
  <study_first_submitted_qc>February 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mazandaran University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Athena Sharifi Razavi</investigator_full_name>
    <investigator_title>Assistant Professor in Neurology</investigator_title>
  </responsible_party>
  <keyword>ESUS</keyword>
  <keyword>DOACS</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

